

Freedom of Information Request	FOI 21-538	11 th January 2022
--------------------------------	------------	-------------------------------

What steps has your CCG/Trust taken to ensure compliance with the mandatory NICE tag 664 for Saxenda. If none, what plans are in place to address this?

Have patients that are eligible to utilise the NICE approved product Saxenda been able to access this product? If so please provide the volume, or if not, please provide any current plans to address this.

When NICE TA664 was published in 2020, a treatment pathway for the use of Saxenda for the management of Overweight and Obesity was developed with our local weight management service team. This was agreed at our Medicines and Therapeutics Committee and Saxenda was included on our local formulary, for use in our weight management clinics, in line with the NICE criteria.

As of December 2021, 24 patients have been started on Saxenda within the Health Board.